Skip to main content

A Taxonomy for Drugs: 2 - Stereochemistry


The next area for consideration in our descriptive taxonomy for drugs is stereochemistry. There are many differing types of stereoisomers encountered in general chemistry, and the area is complex, but the majority of these are not relevant for drug discovery; for example atropisomers, although an important effect is not important for among drug substances. The most significant category of stereochemistry for drug like molecules involves chiral centers at sp3 hybridised carbon atoms connected to four chemically distinct atoms (often giving rise to enantiomerism). Another relevant case of stereoisomerism for drugs are diastereoisomers, these are stereoisomers that are not enantiomers, and include cis-/trans- (E-/Z-) configuration of alkenes.

So for Drug_Stereochemistry_Class, a drug can be:
  • Chiral - containing a single defined stereoisomer of the drug substance, and which lacks an internal plane of symmetry.
  • Racemic - containing a mixture of stereoisomers of the drug substance.
  • Achiral - composed of a drug substance that does not display chirality.
  • Other - displaying a physiologically relevant stereochemical property not covered by the classes above.
The vast majority of biological monomers (e.g. amino acids, nucleotides, sugars)  are chiral, and polymers of these are also chiral (so biological drugs and drug targets within the body). So biological drugs are 'chiral', but since it is so ubiquitous for molecules of this class, the convention is to ignore the issue of chirality for biologicals. For small molecule drugs, the importance is more significant, both scientifically and commercially, and several drugs which were initially synthesized and marketed as racemic mixtures, have subsequently been developed in a chirally pure form. An example of this is Omeprazole, which was subsequently replaced by the 'active' S-enantiomer Esomeprazole. By convention, USANs and INNs for chirally distinct forms of a molecule have either ar- as a prefix for R-configuration and es- as a prefix for S-configuration forms. There is no correlation between the +/- labelling and R/S labelling of chirally active molecules. Previously, the USANs/INNs of chirally pure drugs were often denoted with levo- and dextro- prefices.

It is important to note that since drugs tend to interact with chiral receptors, enantiomers will have different binding affinities against a target (or set of targets), metabolic routes, side-effects, half-lives, etc., and so in general there is usually more interest in developing a chirally pure or achiral drug. Chiral centers often add significantly to the synthetic complexity and cost of manufacture of a drug, and so again there are pressures to develop achiral drugs where possible. So as a general rule, achiral drugs are 'preferred' over chiral drugs which in turn are preferred over racemic drugs. There is a fuller discussion of isomerism and drug development here.

Although most chirality in drugs occurs at sp3 carbon atoms, an important and often neglected case is for sulfoxides, where the geometry around the sulphur atom is tetrahedral, and optically active isomers are possible.

For example:

Sildenafil is an achiral drug.
Levodopa is a chiral drug.
Armodafanil is a chiral drug (containing a chiral sulfoxide).
Citalopram is a racemic drug.
Abciximab is a chiral drug.

Comments

jpo said…
Oh, I forgot to say. Enatiomers will have identical physical properties (like logP, logS, etc), diastereoisomers won't.

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

ChEMBL 26 Released

We are pleased to announce the release of ChEMBL_26 This version of the database, prepared on 10/01/2020 contains: 2,425,876 compound records 1,950,765 compounds (of which 1,940,733 have mol files) 15,996,368 activities 1,221,311 assays 13,377 targets 76,076 documents You can query the ChEMBL 26 data online via the ChEMBL Interface and you can also download the data from the ChEMBL FTP site . Please see ChEMBL_26 release notes for full details of all changes in this release. Changes since the last release: * Deposited Data Sets: CO-ADD antimicrobial screening data: Two new data sets have been included from the Community for Open Access Drug Discovery (CO-ADD). These data sets are screening of the NIH NCI Natural Product Set III in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296183, DOI = 10.6019/CHEMBL4296183) and screening of the NIH NCI Diversity Set V in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296182, DOI = 10.601